Listen
AGRASTAT
Reason for request
New indication.
Unfavourable opinion for reimbursement in the reduction of the risk of major cardiovascular events in patients with acute myocardial infarction (STEMI) intended for percutaneous coronary intervention (PCI).
Role in the care pathway?
In the event of coronary syndromes with ST elevation undergoing PCI, patients should be given acetylsalicylic acid (ASA) and an oral P2Y12 receptor inhibitor, prasugrel or ticagrelor or clopidogrel, as soon as possible. Injection with intravenous cangrelor may be considered in patients without prior P2Y12 inhibitor therapy in whom the oral form is not possible. An anticoagulant therapy (unfractionated heparin) should be co-administered with the antiplatelet therapy.
Role of the medicinal product in the care pathway
AGRASTAT (tirofiban) has no role in the reduction of the risk of major cardiovascular events in patients with acute myocardial infarction (STEMI) intended for percutaneous coronary intervention (PCI).
Clinical Benefit
| Insufficient |
The clinical benefit of AGRASTAT (tirofiban) is insufficient to justify its funding by the French national health insurance system in the reduction of the risk of major cardiovascular events in patients with acute myocardial infarction (STEMI) intended for percutaneous coronary intervention (PCI). |
Clinical Added Value
| Not applicable |
